Pozen licenses migraine med to J&J; Bayer prevails in Yasmin patent fight;

@FiercePharma:  With Sanofi-Merck deal off, look for animal health M&A. Item | Follow @FiercePharma

> Pozen licensed some Latin American rights of its migraine drug, sold in the U.S. as Treximet, to a Johnson & Johnson unit for an undisclosed sum and milestone payments. Report

> Bayer won a UK court ruling upholding the validity of two patents for its birth-control pill Yasmin after a challenge by Hungary's Gedeon Richter. Item

> Pfizer has confirmed its plant in Shanbally, Ireland, will close in August with the loss of 75 full-time jobs if the company does not find a buyer for the facility. News

> Amgen's Prolia continues to improve bone mineral density in post-menopausal women treated with the drug for up to five years, according to new data. Article

> GlaxoSmithKline CEO Andrew Witty stunned Philadelphia Mayor Nutter with an unexpected pledge of $5 million for programs to inspire the city's young people. Item

> Eisai's injectible breast cancer drug Halaven has been approved by European regulators. News

> Amgen may introduce its first dividend next month, rewarding investors whose stock in the world's largest biotechnology company has fallen 33 percent since 2006, even as its cash hoard grew to $17.4 billion. Report

> Gilead Sciences sold $1 billion of senior unsecured floating-rate notes, said IFR, a Thomson Reuters service. Story

> Taking Takeda's diabetes drug Actos every day reduced the chance of developing Type 2 diabetes by two-thirds in people whose obesity, ethnicity, family history and other factors put them at high risk, researchers said. Article

> Researchers identified a genetic variation that appears linked to adverse reactions to the commonly used epilepsy drug carbamazepine. News

Biotech News

@FierceBiotech: Which are the best dealmakers in the biopharma business? Item | Follow @FierceBiotech

@JohnCFierce: Tiny San Diego-based Novalar says that it will shut down now that it has sold its only product. Report | Follow @JohnCFierce

> NeuroSearch shares nosedive after FDA blocks Huntington's drug app. Story

> Supreme Court OKs biotech lawsuits based on adverse events. Article 

Vaccines News

> Skipped MMR vaccines lead to oubreak in Minnesota. Item

> Promising protein may yield TB vax. News

> Inovio gets DNA vaccine grant from DoD. Report 

> Novartis gains majority ownership of Zhejiang Tianyuan. Story

Manufacturing News

> FDA steps up counterfeit drug investigations. Story

> KV blinks, but Makena pricing tactic common. Item 

> India sets tone for drug production in Nigeria. Article

> Science uses art tool to ID drug colors. Report

> Fabrazyme falls victim to fill/finish. Story 

> UK pushes continuous manufacturing. News 

And Finally... New HIV infections in the UK have nearly doubled over the past decade, prompting health officials to recommend an ambitious testing campaign to catch and treat cases early. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.